Determination of temozolomide concentration in human plasma by liquid chromatographytandem mass spectrometry

Gang CHEN,Jin WANG,Ze-juan WANG,Xiao-yi KONG,Xiao-na LIU,Chen LIU,Ying LIU,Lu QI,Bao-li ZHOU,Wen-bin LI,Xing-he WANG

DOI: https://doi.org/10.13699/j.cnki.1001-6821.2018.09.029

2018-01-01

Abstract:Objective To develop a rapid,sensitive and specific analytical method based on liquid chromatographytandem mass spectrometry (LC-MS/MS) for the determination of temozolomide concentration in human plasma in equivalence trial clinical trial.Methods After protein sediment by methanol and acetonitrile (1 ∶ 2,0.1％ formic acid),the analyte and internal standard were separated on a Kinetex Ci8 column (3.0 mm × 50 mm) using a isocratic elution consisting of 0.1％ formic acid water solution 0.1％ formic acid and methanol (9∶1) as the mobile phase at a flow rate of 0.3 mL · min-1 The detection was performed using an API 5500 QTrap mass spectrometer in the positive electrospray ionization (ESI) mode.The multiple reaction monitoring (MRM) transitions were m/z 195.1→m/z 138.0 for the analyte and m/z 198.1→m/z 138.0 for temozolomide-d3.Results The calibration curve exhibited a linear dynamic range of 0.05-30 μg · mL-1 (r ＞ 0.997 3).The intra-and inter-day precisions (relative standard deviation,RSD) were 1.06％-7.13％ and 1.80％-5.19％.The intraand interday precisions were 91.02％-109.33％ and 95.14％-101.22％.The recoveries and matrix effects were satisfactory in all the biological matrices examined.Conclusion This method was successfully used for the determination of temozolomide concentration in human plasma in equivalence trial.